Novo Integrated Sciences, Inc. (NVOS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Novo Integrated Sciences, Inc. (NVOS) trades at $0.00 with AI Score 51/100 (Grade B). Novo Integrated Sciences, Inc. Market cap: $69,056, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for NVOS: NVOS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NVOS against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NVOS: the 7 perspectives are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Novo Integrated Sciences, Inc. (NVOS) Healthcare & Pipeline Overview
Novo Integrated Sciences, Inc. is a healthcare provider operating 16 clinics, offering a broad spectrum of primary care services from physiotherapy to advanced neurological rehabilitation, alongside developing health and wellness products. The company targets diverse demographics, including eldercare, and integrates telemedicine, positioning itself in the vertically integrated healthcare delivery market.
What Is the Investment Thesis for NVOS?
Novo Integrated Sciences, Inc. presents an integrated healthcare delivery model, leveraging its network of 16 wholly-owned clinics to offer a broad spectrum of primary healthcare services and develop health and wellness products. Key value drivers include its diverse service portfolio, spanning from general physiotherapy to specialized neurological rehabilitation and eldercare, which addresses a wide demographic need. The company's integration of telemedicine and remote patient monitoring positions it to capitalize on evolving healthcare delivery trends. Growth catalysts include potential expansion of its clinic network, increased adoption of digital health services, and the growing demand for specialized eldercare due to an aging population. The company's gross margin of 43.2% indicates efficiency in service delivery. However, investors must consider significant risks, particularly the ongoing negative profit margin of -121.3%, which raises concerns about operational sustainability. The stock's high Beta of 5.99 suggests substantial market volatility, and its OTC Other listing implies less stringent disclosure requirements and potential liquidity challenges, necessitating thorough due diligence.
Based on FMP financials and quantitative analysis
NVOS Key Highlights
- Gross Margin of 43.2% reflects the company's operational efficiency in service delivery and product sales.
- Profit Margin of -121.3% indicates significant ongoing operational losses.
- Beta of 5.99 suggests high market volatility, with the stock price potentially moving significantly more than the broader market.
- Operates a network of 16 wholly-owned clinics, providing a direct service delivery infrastructure.
- Employs 115 individuals across its healthcare services and product manufacturing and development segments.
Who Are NVOS's Competitors?
NVOS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| DCGO DocGo Inc. | $0.59 | +5.81% | $58.07M | 51 |
| JYNT The Joint Corp. | $9.16 | +2.10% | $130.55M | 51 |
| AMS American Shared Hospital Services | $1.48 | -0.67% | $9.80M | 51 |
| THC Tenet Healthcare Corporation | $206.91 | +1.56% | $17.82B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NVOS's Key Strengths?
- Vertically integrated healthcare delivery model encompassing services and product development.
- Diverse and comprehensive service portfolio catering to pediatric, adult, and geriatric populations.
- Operates a network of 16 wholly-owned clinics, providing a tangible operational base.
- Focus on high-demand areas like eldercare and advanced neurological rehabilitation.
- Integration of medical technology, including telemedicine and remote patient monitoring.
What Are NVOS's Weaknesses?
- Significant ongoing negative profit margin of -121.3% impacting financial sustainability.
- Trades on the OTC Other tier, implying less stringent disclosure and potential liquidity concerns.
- High market volatility indicated by a Beta of 5.99.
- Reliance on an unknown disclosure status for financial reporting, hindering investor transparency.
- Limited public information regarding CEO's specific track record and achievements.
What Could Drive NVOS Stock Higher?
- Potential expansion of the company's clinic network into new geographic markets or through strategic acquisitions, increasing service capacity.
- Introduction of new specialized health and wellness products, diversifying revenue streams and enhancing product offerings.
- Increasing adoption and utilization of telemedicine and remote patient monitoring services, expanding patient reach and service efficiency.
- Growth in demand for eldercare physiotherapy and occupational therapy services driven by demographic trends and an aging population.
What Are the Key Risks for NVOS?
- Financial-distress signal — its Altman Z-Score of -4.47 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-81.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Sustained negative profit margin of -121.3%, which poses a significant challenge to the company's long-term operational sustainability and profitability.
- Inherent risks associated with its OTC Other listing, including potential for lower liquidity, less stringent disclosure requirements, and limited analyst coverage.
- High market volatility, as indicated by a Beta of 5.99, which could lead to significant and rapid fluctuations in the company's stock price.
- Intense competition within the fragmented healthcare services and product market from both local independent clinics and larger healthcare systems.
- Regulatory changes in the healthcare sector, which could impact reimbursement rates, operational compliance, or the cost of doing business.
What Are the Growth Opportunities for NVOS?
- Expansion of Integrated Healthcare Clinic Network: The market for physical therapy, occupational therapy, and chiropractic services is substantial and growing, driven by chronic conditions, sports injuries, and an aging population. NVOS's current 16 clinics provide a foundational infrastructure for strategic expansion into new geographic markets or through targeted acquisitions. Leveraging its integrated service model, which combines various therapies with product offerings, the company could capture a larger patient base. This organic or inorganic growth strategy could significantly increase service capacity, patient reach, and ultimately, revenue streams over the next 3-5 years, enhancing its market footprint and operational scale.
- Telemedicine and Remote Patient Monitoring Adoption: The global telemedicine market is experiencing significant growth, projected to reach hundreds of billions of dollars by the late 2020s, driven by convenience, accessibility, and cost-effectiveness. NVOS's existing telemedicine consultations and remote patient monitoring services position it to capitalize on this trend. Expanding these digital health offerings can extend reach beyond physical clinic locations, improve patient engagement, and potentially reduce operational overhead. This strategy allows the company to target a broader patient demographic seeking flexible healthcare solutions, enhancing service delivery efficiency and market penetration over the next 2-4 years.
- Specialized Eldercare Services Market: The aging global population presents a robust and expanding market for eldercare physiotherapy and occupational therapy services, particularly within long-term care homes and retirement communities. NVOS's established programs, including comprehensive eldercare physiotherapy, group exercise classes, and fall prevention initiatives, directly address critical needs in this demographic. Deepening penetration into this segment, potentially through strategic partnerships with eldercare facilities or by expanding community-based home care services, offers a stable and growing revenue stream over the long term (5+ years), capitalizing on demographic shifts and increasing demand for senior care.
- Development and Distribution of Health and Wellness Products: The global health and wellness market, encompassing nutritional supplements, assistive devices, and rehabilitation aids, is a multi-trillion-dollar industry with consistent growth. NVOS's segment for developing and distributing bespoke health and wellness product solutions allows it to capture additional revenue beyond direct services. Innovating and expanding this product line, potentially through e-commerce channels or strategic retail partnerships, could create a diversified revenue stream, enhance brand recognition, and foster patient loyalty by offering complementary solutions to its services within the next 3-5 years.
- Focus on Neurological and Specialized Rehabilitation: Conditions like stroke, traumatic brain injuries, and PTSD require highly specialized and often long-term rehabilitation. The market for neurological rehabilitation is significant and often underserved. NVOS's offerings, including advanced rehabilitation for neurological conditions, vestibular therapy, concussion management, and trauma-sensitive yoga, position it to become a leader in these niche, high-value services. Expanding specialized programs, investing in advanced therapeutic technologies, and building expertise in these complex areas could attract a premium patient segment and significantly differentiate the company over the next 3-7 years.
What Opportunities Does NVOS Have?
- Growing demand for eldercare services driven by an aging global population.
- Increasing adoption and market expansion of telemedicine and remote patient monitoring solutions.
- Potential for expansion of the clinic network into new geographic markets or through strategic acquisitions.
- Development and distribution of new bespoke health and wellness products to diversify revenue streams.
- Further specialization in advanced neurological rehabilitation and other niche high-value therapeutic areas.
What Threats Does NVOS Face?
- Intense competition from established local clinics, large hospital systems, and specialized rehabilitation centers.
- Potential for adverse regulatory changes in the healthcare sector impacting reimbursement rates or operational compliance.
- Economic downturns or changes in consumer spending patterns affecting demand for elective healthcare services.
- Technological disruption from larger, better-funded healthcare technology companies.
- Challenges in attracting and retaining qualified healthcare professionals in a competitive labor market.
What Are NVOS's Competitive Advantages?
- Vertically integrated healthcare delivery model, allowing for comprehensive control over service quality, patient experience, and product development from consultation to rehabilitation.
- Diverse and comprehensive service portfolio, addressing a wide range of conditions and demographics, which reduces reliance on a single specialty or patient group.
- Established network of 16 wholly-owned clinics, providing a physical infrastructure and operational base for consistent service delivery and local market presence.
- Integration of medical technology, including telemedicine and remote patient monitoring, enhancing accessibility, convenience, and potentially patient engagement beyond traditional clinic visits.
- Specialization in niche, high-demand areas like advanced neurological rehabilitation and eldercare, which require specific expertise and tailored programs.
What Does NVOS Do?
Novo Integrated Sciences, Inc. (NVOS), established in 2000 and headquartered in Bellevue, Washington, functions as a subsidiary of ALMC-ASAP Holdings, Inc., delivering a diverse array of primary healthcare services and related products. The company's operations are segmented into Healthcare Services and Product Manufacturing and Development. Within its Healthcare Services segment, NVOS provides an extensive portfolio of therapeutic approaches, including physiotherapy, chiropractic care, manual manipulation, occupational therapy, and massage therapy. Specialized treatments further enhance their offerings, encompassing acupuncture, functional dry needling, chiropody, and advanced rehabilitation tailored for complex conditions such as stroke, traumatic brain injuries, and other neurological impairments. The company also offers kinesiology, vestibular therapy, concussion management, and baseline testing, alongside unique programs like trauma-sensitive yoga and meditation designed for brain injury recovery and PTSD. Beyond these, services extend to women's pelvic health, sports medicine, provision of assistive devices, dietetics, holistic nutrition, fall prevention education, sports team conditioning, and private personal training. Novo Integrated Sciences, Inc. is dedicated to the comprehensive assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of a wide range of orthopedic, musculoskeletal, sports injury, and neurological conditions. These services cater to all age demographics, from pediatric and adult patients to geriatric populations. For older adults, the company delivers extensive eldercare physiotherapy within long-term care homes, retirement communities, and through community-based home care, including group exercise classes and fall prevention initiatives, in addition to services at its outpatient clinics. Similarly, occupational therapy services for the elderly are extended to retirement communities and long-term care facilities. The company also incorporates medical technology, offering telemedicine consultations and remote patient monitoring, and actively develops and distributes bespoke health and wellness product solutions. NVOS operates a network of 16 wholly-owned clinics, employing 115 individuals.
What Products and Services Does NVOS Offer?
- Operate a network of 16 wholly-owned primary healthcare clinics across various locations.
- Provide a wide range of therapeutic services including physiotherapy, chiropractic care, occupational therapy, and massage therapy.
- Offer specialized treatments such as acupuncture, functional dry needling, chiropody, and advanced rehabilitation for neurological conditions.
- Deliver comprehensive eldercare physiotherapy and occupational therapy services within long-term care homes, retirement communities, and through home care.
- Integrate medical technology by offering telemedicine consultations and remote patient monitoring.
- Develop and distribute bespoke health and wellness product solutions to complement their service offerings.
- Focus on the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of orthopedic, musculoskeletal, sports injury, and neurological conditions.
- Cater to a broad patient demographic, spanning pediatric, adult, and geriatric populations.
How Does NVOS Make Money?
- Generates revenue primarily from direct patient services provided across its network of 16 wholly-owned clinics.
- Derives income from specialized therapeutic programs, including advanced neurological rehabilitation, sports medicine, and comprehensive eldercare services.
- Monetizes through the development, manufacturing, and distribution of proprietary health and wellness product solutions.
- Expands service reach and revenue streams via telemedicine consultations and remote patient monitoring platforms.
- Offers diverse programs such as fall prevention education, sports team conditioning, and private personal training, contributing to service-based income.
What Industry Does NVOS Operate In?
Novo Integrated Sciences, Inc. operates within the dynamic Healthcare sector, specifically in the Medical - Care Facilities industry. This industry is characterized by increasing demand driven by an aging global population, a rise in chronic conditions, and growing awareness of preventative and rehabilitative care. Key market trends include the expansion of integrated care models, the increasing adoption of telemedicine for enhanced accessibility, and a growing focus on specialized therapies for neurological and musculoskeletal conditions. The competitive landscape is fragmented, comprising local independent clinics, larger regional healthcare systems, and specialized rehabilitation centers. Novo Integrated Sciences, Inc. positions itself through a vertically integrated model, offering a broad range of services from primary care to advanced rehabilitation and product development. Its network of 16 clinics and focus on diverse demographics, including eldercare, allows it to carve out a niche in a competitive market, aiming to provide comprehensive solutions under one umbrella.
Who Are NVOS's Key Customers?
- Pediatric patients requiring various therapeutic interventions for developmental or injury-related conditions.
- Adults seeking treatment for orthopedic, musculoskeletal, sports injury, and general pain management needs.
- Geriatric populations in long-term care homes, retirement communities, and those receiving community-based home care, requiring eldercare physiotherapy and occupational therapy.
- Individuals recovering from complex neurological conditions such as stroke, traumatic brain injuries, and PTSD, seeking advanced rehabilitation.
- Patients utilizing digital health services for telemedicine consultations and remote patient monitoring for ongoing care.
Company Profile
Novo Integrated Sciences, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Bellevue, US. The company is led by CEO Robert Mattacchione. NVOS has traded publicly since 2021.
F-Score 3/9Financial Health
Novo Integrated Sciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.47 places it in the distress zone, a signal of elevated financial risk.
ROE -81%Key Financial Metrics
Return on equity for Novo Integrated Sciences, Inc. stands at -81.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -50.2%, showing how much profit it generates from its asset base. A current ratio of 0.37 means current liabilities exceed short-term assets, a liquidity point worth watching.
NVOS Valuation & Market Position
With a 69K market cap, Novo Integrated Sciences, Inc. sits in the micro-cap segment of the market. Relative to its peer group, NVOS's quantitative score of 51/100 is roughly in line with the peer average of 60/100.
Net buyingInsider Activity
The most recent 9 insider filings for Novo Integrated Sciences, Inc. break down as 0 sales and 9 purchases. On net that is roughly 2.3M shares acquired (about $708K) — insiders putting money in tends to read as conviction.
NVOS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Vertically integrated healthcare delivery model encompassing services and product development.
- Diverse and comprehensive service portfolio catering to pediatric, adult, and geriatric populations.
- Operates a network of 16 wholly-owned clinics, providing a tangible operational base.
- Focus on high-demand areas like eldercare and advanced neurological rehabilitation.
Bear Case
- Significant ongoing negative profit margin of -121.3% impacting financial sustainability.
- Trades on the OTC Other tier, implying less stringent disclosure and potential liquidity concerns.
- High market volatility indicated by a Beta of 5.99.
- Reliance on an unknown disclosure status for financial reporting, hindering investor transparency.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
NVOS Latest News
No recent news available for NVOS.
NVOS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NVOS.
Price Targets
Wall Street price target analysis for NVOS.
NVOS MoonshotScore
What does this score mean?
The MoonshotScore rates NVOS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Robert Mattacchione
Chief Executive Officer
Robert Mattacchione serves as the Chief Executive Officer of Novo Integrated Sciences, Inc. While specific details regarding his educational background, prior career history, and previous executive roles are not provided in the available source data, he is responsible for managing the company's 115 employees. His leadership is central to the operational oversight of Novo Integrated Sciences' diverse healthcare services and product development segments, guiding the company's strategic direction from its Bellevue, Washington headquarters.
Track Record: Specific achievements, strategic decisions, and company milestones directly attributable to Mr. Mattacchione's leadership are not detailed in the provided source information. His tenure involves overseeing the company's network of 16 wholly-owned clinics and its dual focus on healthcare services and product manufacturing and development. The company's establishment in 2000 and its operational evolution have occurred under the broader leadership framework.
NVOS OTC Market Information
Novo Integrated Sciences, Inc. trades on the OTC Other tier of the OTC market. This tier is distinct from major exchanges like the NYSE or NASDAQ, which have more stringent listing requirements regarding financial reporting, corporate governance, and minimum share prices. The 'OTC Other' tier typically includes companies that do not meet the reporting standards for higher OTC tiers like OTCQX or OTCQB, or those that are not required to report to the SEC. This often implies less public information and potentially higher risk for investors compared to exchange-listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Less stringent financial reporting and disclosure requirements compared to major exchanges, leading to reduced transparency.
- Potential for lower trading volume and wider bid-ask spreads, resulting in reduced market liquidity and difficulty in executing trades.
- Higher susceptibility to price manipulation due to less regulatory oversight and lower trading activity.
- Limited access to institutional capital and analyst coverage, which can impact market visibility and investor interest.
- Increased volatility and risk of significant price fluctuations, as indicated by a high Beta of 5.99.
- Thoroughly review all available financial statements and corporate filings, regardless of frequency or format.
- Investigate the company's business operations, revenue streams, and competitive landscape in detail, seeking independent verification.
- Assess the management team's experience and track record, looking for any publicly available information or independent reviews.
- Understand the company's capital structure, outstanding shares, and any potential for future dilution.
- Evaluate the market for the company's products and services, including growth prospects and the regulatory environment.
- Consider the potential for limited liquidity and the implications for entry and exit strategies for investments.
- Seek independent legal and financial advice to fully understand the risks associated with OTC investments.
- Operates a network of 16 wholly-owned physical clinics, indicating tangible assets and established operational infrastructure.
- Established in 2000, suggesting a long operational history and experience in the healthcare sector.
- Offers a diverse array of primary healthcare services and product development, demonstrating a comprehensive business model.
- Functions as a subsidiary of ALMC-ASAP Holdings, Inc., implying a broader corporate structure and potential backing.
NVOS Healthcare Stock FAQ
What does Novo Integrated Sciences, Inc. do?
Novo Integrated Sciences, Inc. (NVOS) is a healthcare company that provides a diverse range of primary healthcare services and related products through its two main segments: Healthcare Services and Product Manufacturing and Development. The company operates 16 wholly-owned clinics, offering therapies such as physiotherapy, chiropractic care, occupational therapy, and specialized rehabilitation for conditions like stroke and traumatic brain injuries. They also cater to eldercare within long-term care facilities and integrate medical technology like telemedicine. Additionally, NVOS develops and distributes bespoke health and wellness product solutions, aiming to offer comprehensive care across pediatric, adult, and geriatric populations from its Bellevue, Washington headquarters.
How does Novo Integrated Sciences, Inc. generate revenue in the healthcare sector?
Novo Integrated Sciences, Inc. generates revenue through multiple streams within the healthcare sector. A primary source is its direct patient services, delivered across its network of 16 wholly-owned clinics, which encompass a broad array of therapeutic interventions like physiotherapy, chiropractic care, and specialized rehabilitation programs. Revenue also stems from its dedicated eldercare services provided within long-term care homes and retirement communities. Furthermore, the company monetizes its expertise by developing and distributing bespoke health and wellness product solutions. The integration of telemedicine consultations and remote patient monitoring also contributes to its revenue by expanding service accessibility and reach to a wider patient base.
What are the primary risks associated with investing in Novo Integrated Sciences, Inc., particularly given its OTC listing?
Investing in Novo Integrated Sciences, Inc. carries several notable risks. Operationally, the company faces a significant challenge with an ongoing negative profit margin of -121.3%, raising concerns about its financial sustainability. As an OTC Other listed stock, NVOS is subject to less stringent disclosure requirements compared to major exchanges, leading to reduced transparency and potentially limited public information. This OTC listing also typically results in lower trading volumes and wider bid-ask spreads, contributing to lower liquidity and making it more difficult for investors to buy or sell shares efficiently. The stock's high Beta of 5.99 indicates substantial market volatility, suggesting that its share price could experience significant fluctuations. Additionally, the company operates in a highly competitive healthcare services market, facing competition from various providers.
What are the key factors to evaluate for NVOS?
Novo Integrated Sciences, Inc. (NVOS) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does NVOS data refresh on this page?
NVOS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NVOS's recent stock price performance?
Novo Integrated Sciences, Inc. (NVOS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Vertically integrated healthcare delivery model encompassing services and product development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NVOS overvalued or undervalued right now?
Valuing Novo Integrated Sciences, Inc. (NVOS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NVOS?
Before investing in Novo Integrated Sciences, Inc. (NVOS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information regarding CEO's specific background, track record, and tenure is not provided in the source data.
- Specific details on OTC disclosure level, liquidity metrics, and analyst consensus are not available in the provided source material.